DROIA is a venture investor, exclusively focused on the development of oncology therapies. We are dedicated to making a difference in the fight against cancer. We have adopted a unique investment model to accelerate development in our portfolio companies. We aim to bring promising therapies to patients faster, creating both patient benefit and shareholder value. Hence our name: Double Return On Investment, Accelerated: DROIA. The holding is funded by European private investors and operates from offices in Luxembourg and Brussels. We invest worldwide.
DROIA makes select investments in early stage drug development companies with solid preclinical proof of concept. Our investment decisions are based on breakthrough potential as evidenced by strong data. We welcome any technology with great promise and constantly analyze new discoveries and companies. DROIA invests by participating in companies or by creating new ventures around promising technology. We want to support our companies at least up to clinical proof of concept, yet we can extend our investment horizon if remaining with a company can further benefit its development.
DROIA is a hands-on investor and can actively participate in the development of the portfolio companies. We have an in-house expert team with experience in clinical oncology, drug development and entrepreneurship. We help by providing not just financial means, but also people and assistance on scientific, preclinical, clinical & CMC development, on IP & regulatory, on licensing, finance & transactions and on company building. Our network of oncology leaders gives us access to top-level institutions and KOL’s around the world and allows our companies to benefit from a global knowledge base. We firmly believe that our approach can improve and accelerate the development of the cancer therapies that will come out of today’s exciting scientific findings.
ARCUS Biosciences (Hayward, California) develops a broad portfolio of small-molecule and antibody compounds to assemble its proprietary I/O combinations. The company targets tumor related immune suppression, enhanced APC function and immune cell efficacy.
Aura Biosciences (Cambridge, Massachusetts) develops drugs using tumor targeted viral-like nanoparticles which can encapsulate a wide range of payloads. Aura has been granted Orphan Disease Designation by the FDA for the drug AU-011 for the treatment of Ocular Melanoma.
Bioncotech (Madrid, Spain) develops nanocomplexes of synthetic dsRNA that induce powerful immune responses as well as apoptosis in cancer cells. Bioncotech is clinically evaluating different immune oncology combination strategies.
Convert Pharmaceuticals (Belgium) develops hypoxia-activated cytotoxic small molecules, complementing existing therapies in treatment resistant areas of solid tumours while maintaining a favourable toxicity profile.
Cristal Therapeutics (Maastricht, The Netherlands) develops a polymeric nanoparticle drug delivery platform enhancing the PK properties of chemotherapeutic or nucleotide payloads and improving their uptake in the tumor micro-environment.
NormOxys (Boston, Massachusetts) modulates the tumor microenvironment, enhancing the patient’s response to other therapies. NormOxys’ drug candidates reverse hypoxia and normalize vasculature around cancer cells, sensitizing tumors to immune therapy, chemotherapy or radiotherapy.
Octimet (Beerse, Belgium) is developing a new generation of highly selective MET kinase activity inhibitors with augmented therapeutic index. The lead compound was licensed from Janssen Pharmaceutica and will be advanced by employing innovative clinical and pharmacodynamic biomarker-based approaches.
PACT (Hayward, California) is utilizing proprietary technology to discontinuously advance the feasibility, affordability and clinical utilization of personalized neoantigen-specific adoptive cell therapy for cancer.
Tusk Therapeutics (Stevenage, UK) is developing novel immune modulating therapeutics based on an in-depth understanding of the innate and adaptive immune system. The company is establishing a primary pipeline of antibodies to harness the immune system against cancer.
* representing XIA bvba
* representing Onko bvba
DROIA is currently recruiting for its investment and development team. The team scouts for new opportunities, evaluates companies and projects, manages the investment or exit process and works with the portfolio companies on their progress.
Team members work closely with the portfolio companies at management or board level, and play a hands-on role in all aspects of the drug development process.
DROIA is an entrepreneurial environment, where everyone is above all committed to making a difference in the fight against cancer.
Applicants should have relevant experience in biomedical science, drug development and / or life science investing.
35, Allée Scheffer
Tel. +352 203 01 236
Tel. +32 2 880 67 30